SCHEMBL17834203

SCHEMBL17834203

c1c(C2CCCCN2)nn2c(N3CCOCC3)c3c(nc12)CCCC3

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.57
HSD17B10 Q99714 4/20 0.57
LMNA P02545 4/20 0.57
MAPT P10636 3/20 0.57
TSHR P16473 3/20 0.57
HTT P42858 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
ALOX15 P16050 1/20 0.57
ALDH1A1 P00352 3/20 0.53
HPGD P15428 3/20 0.53
NPC1 O15118 1/20 0.53
CASP3 P42574 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
SENP8 Q96LD8 1/20 0.53
SENP7 Q9BQF6 1/20 0.53
SENP6 Q9GZR1 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17822354 0.99 KDM4E (0.56) KDM4EHSD17B10LMNAMAPTTSHR
SCHEMBL17822399 0.98 KDM4E (0.54) KDM4EHSD17B10LMNAMAPTTSHR
SCHEMBL17822366 0.91 KDM4E (0.46) KDM4EHSD17B10LMNAMAPTTSHR
SCHEMBL17822421 0.90 KDM4E (0.46) KDM4EHSD17B10LMNAMAPTTSHR
SCHEMBL17822364 0.89 KDM4E (0.48) KDM4EHSD17B10LMNAMAPTTSHR
SCHEMBL17822416 0.89 KDM4E (0.43) KDM4EHSD17B10LMNAMAPTTSHR
SCHEMBL2737999 0.81 TSHR (0.53) KDM4EHSD17B10LMNAMAPTTSHR
SCHEMBL17827741 0.80 TSHR (0.42) KDM4EHSD17B10LMNAMAPTTSHR
SCHEMBL17822388 0.79 ALDH1A1 (0.36) KDM4EHSD17B10MAPTTSHRHTT
SCHEMBL17822409 0.79 ALDH1A1 (0.36) KDM4EHSD17B10LMNAMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3230288-B1 PIPERIDINE SUBSTITUTED TRICYCLIC PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) JANSSEN SCIENCES IRELAND UC (IE) 2018-11-21 EP disclosed
US-10131673-B2 Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) JANSSEN SCIENCES IRELAND UC (IE) 2018-11-20 US disclosed
US-20170349602-A1 PIPERIDINE SUBSTITUTED TRICYCLIC PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) JANSSEN INFECTIOUS DISEASES BVBA (BE) 2017-12-07 US disclosed
US-20170349602-A1 PIPERIDINE SUBSTITUTED TRICYCLIC PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) JANSSEN INFECTIOUS DISEASES BVBA (BE) 2017-12-07 US disclosed
WO-2016091791-A1 PIPERIDINE SUBSTITUTED TRICYCLIC PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) JANSSEN SCIENCES IRELAND UC (IE) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10131673-B2 Piperidine substituted tricyclic pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV) PIR, ZC3HAV1, MAVS KDM4E 2931/4885HSD17B10 4717/4885LMNA 2153/4885
US-20170349602-A1 PIPERIDINE SUBSTITUTED TRICYCLIC PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) ZC3HAV1, MAVS, PIR KDM4E 3446/4885HSD17B10 4714/4885LMNA 2470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.